Evidence map›Paper›PMID 34299462›Full record

ArticleMolecules (Basel, Switzerland)2021

Discovery of Novel 2,4-Dianilinopyrimidine Derivatives Containing 4-(Morpholinomethyl)phenyl and

Chun Han, Kemin Shen, Shijun Wang, Zhijun Wang, Feng Su, Xi Wu, Xiaoqin Hu, Mengyao Li, Jing Han, Lintao Wu

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Development of FAK Inhibitors: A Five-Year Update.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Chun HanDepartment of Chemistry, Changzhi University, Changzhi 046011, China.ORCID 0000-0002-5913-5001
Kemin ShenDepartment of Public Health and Preventive Medicine, Changzhi Medical College, Changzhi 046011, China.
Shijun WangDepartment of Chemistry, Changzhi University, Changzhi 046011, China.ORCID 0000-0002-2243-5545
Zhijun WangDepartment of Chemistry, Changzhi University, Changzhi 046011, China.
Feng SuDepartment of Chemistry, Changzhi University, Changzhi 046011, China.
Xi WuDepartment of Chemistry, Changzhi University, Changzhi 046011, China.
Xiaoqin HuDepartment of Chemistry, Changzhi University, Changzhi 046011, China.
Mengyao LiDepartment of Chemistry, Changzhi University, Changzhi 046011, China.
Jing HanSchool of Chemistry and Materials Science, Jiangsu Normal University, Xuzhou 221116, China.
Lintao WuDepartment of Chemistry, Changzhi University, Changzhi 046011, China.ORCID 0000-0002-8768-9036

Funding

National Natural Science Foundation of China 21402012; 21907010Natural Science Foundation of Shanxi Province 201901D211465
6 · The paper itself

Abstract

Focal adhesion kinase (FAK) is responsible for the development and progression of various malignancies. With the aim to explore novel FAK inhibitors as anticancer agents, a series of 2,4-dianilinopyrimidine derivatives

Indexed as

Antineoplastic AgentsApoptosisBenzamidesCell ProliferationCell SurvivalDrug DesignDrug Screening Assays, AntitumorFocal Adhesion Protein-Tyrosine KinasesHumansMolecular Docking SimulationMolecular StructureMorpholinesNeoplasmsPhenolsProtein Kinase InhibitorsPyrimidinesAntineoplastic AgentsBenzamidesFocal Adhesion Protein-Tyrosine KinasesMorpholinesmorpholinomethylphenolPhenolsProtein Kinase InhibitorsPyrimidinesTAE2262,4-dianilinopyrimidine4-(morpholinomethyl)phenylanticancerFAK inhibitormolecular dockingN-substituted benzamides

Identifiers

PMID34299462
PMCPMC8304610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.